In Part I of this series providing a summary of the mRNA IP and competitive landscape through one year of
Continue Reading The mRNA Patent and Competitive Landscape: Pioneers, Litigation Outlook and Big Pharma’s Next Moves (Part III)
Dan Shores
Dan Shores is a Partner at Rothwell Figg and is a founder of its Boston office. He is passionate about helping his clients build robust patent portfolios, litigate matters (both as plaintiffs and defendants in the U.S. District Courts and in IPR and other post-grant proceedings), protect trade secrets, negotiate strategic collaborations, conduct due diligence and landscape investigations, and prepare for success in funding rounds and exits. Dan is a problem-solver who excels at deciphering key translational aspects of a broad array of technologies to maximize leverage in the context of clients’ desired implementation of such technologies whether as participants in dynamic markets or as first movers. Dan is a registered patent attorney licensed to practice before the United States Patent and Trademark Office, and is admitted to practice law in Massachusetts and in the District of Columbia. He is a member of the bars of the Supreme Court of the United States, United States Court of Appeals for the Federal Circuit, and United States District Court for the District of Massachusetts. Dan lives in Boston with his wife Lindsay, their daughter Audrey, and their two English Bulldogs Jarves and Rosie.
The mRNA Patent and Competitive Landscape: Translate BIO; Arcturus; eTheRNA and Other Startups; and LNP Technology (Part II)
In Part I of this three-part series, we focused on three mRNA technology market players: BioNTech, Moderna and CureVac.
Continue Reading The mRNA Patent and Competitive Landscape: Translate BIO; Arcturus; eTheRNA and Other Startups; and LNP Technology (Part II)
The mRNA Patent and Competitive Landscape Through One Year of the COVID-19 Pandemic–Part I
Shortly after we posted about Moderna, Inc.’s October 2020 pledge not to enforce its COVID-19-related patents during the pandemic, the…
Continue Reading The mRNA Patent and Competitive Landscape Through One Year of the COVID-19 Pandemic–Part I
IP Assignment Considerations for Emerging Companies
Founders of emerging companies must decide early on in their company’s growth cycle whether to require employees to assign their…
Continue Reading IP Assignment Considerations for Emerging Companies
Dana-Farber Launches New Fund to Support Oncology Startups
2021 started off well for Dana-Farber Cancer Institute, with the launch of its new venture fund, Binney Street Capital, …
Continue Reading Dana-Farber Launches New Fund to Support Oncology Startups
Hyundai Buys Majority of Boston Dynamics from SoftBank in $1.1B deal
Hyundai is reportedly in the process of purchasing a large controlling interest in robot innovator Boston Dynamics from SoftBank in
…
Continue Reading Hyundai Buys Majority of Boston Dynamics from SoftBank in $1.1B deal
Emerging Companies: Framework for Leveraging Your IP & Tech
Founders of technology-based companies often recognize very early on that their company’s IP and related technology comprise a significant or…
Continue Reading Emerging Companies: Framework for Leveraging Your IP & Tech
World Economic Forum Releases Top 10 Emerging Technologies of 2020
Quick heads up, the World Economic Forum released a Special Report covering what it considers to the the top 10…
Continue Reading World Economic Forum Releases Top 10 Emerging Technologies of 2020
Breaking Down Moderna’s COVID-19 Patent Pledge: Why Did They Do It?
As Pfizer and BioNTech announced this week that results of their COVID-19 vaccine have exceeded expectations, the technology behind the…
Continue Reading Breaking Down Moderna’s COVID-19 Patent Pledge: Why Did They Do It?
Ryder Launches $50M Venture Fund for Supply Chain Startups
This week, Ryder System, Inc. (NYSE: R), announced a new corporate venture capital fund called RyderVentures.
The fund seeks to…
Continue Reading Ryder Launches $50M Venture Fund for Supply Chain Startups